SCHEMBL23964437

SCHEMBL23964437

CN1CCN(CCc2cccc(C(C)(C)C)c2O)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
MAPT P10636 4/20 0.50
KDM4E B2RXH2 3/20 0.50
CA2 P00918 1/20 0.50
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
POLB P06746 3/20 0.43
TSHR P16473 3/20 0.43
HPGD P15428 3/20 0.43
GAA P10253 2/20 0.43
LMNA P02545 2/20 0.43
THRB P10828 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
SIGMAR1 Q99720 2/20 0.42
ATM Q13315 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
KCNH2 Q12809 2/20 0.41
HSD17B10 Q99714 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23964432 0.86 MEN1 (0.49) CA2POLBLMNAHRH3SIGMAR1
SCHEMBL23964434 0.78 SIGMAR1 (0.52) ALDH1A1KDM4ECA2POLBTSHR
SCHEMBL24127984 0.77 HTR2C (0.48) CA2HTR2AHTR2CHTR2BTSHR
Methylpiperazine SCHEMBL10565136 0.76 CA2 (0.59) ALDH1A1MAPTKDM4ECA2POLB
SCHEMBL23926384 0.75 ERN1 (0.47) ALDH1A1HTR2AHTR2CHTR2BHRH3
SCHEMBL7065972 0.74 CA2 (0.59) ALDH1A1CA2TSHRATMGABRA1
SCHEMBL3809080 0.74 CA2 (0.59) ALDH1A1MAPTKDM4ECA2TSHR
SCHEMBL15248908 0.73 KDM4E (0.66) ALDH1A1MAPTKDM4EPOLBGAA
SCHEMBL430927 0.73 CA2 (0.57) ALDH1A1CA2TSHRATMGABRA1
SCHEMBL57139 0.71 GABRA1 (0.67) ALDH1A1CA2TSHRATMGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 ALDH1A1 2721/4885MAPT 6/4885KDM4E 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.